Day 3: Next Generation Logistics Optimization

8.50 Chair’s Opening Remarks Chair’s Opening Remarks

9.00 INVENTORY MANAGEMENT PANEL: Being Risk-Averse V Being Lean: How Do You Manage The Trade- Off? Wayne Swanton, VP Supply Chain, Watson Pharmaceuticals Mark Holder, Senior Director, Global Supply Planning, AstraZeneca Pharmaceuticals JB Wilcox, Senior Director- Supply Chain, Mylan Michael Trocchia, Director Project Management- Supply Chain Management, Novartis Pharmaceuticals Corporation Roddy Martin, Supply Chain Transformation Thought Leader, Kinaxis Rodney Daugherty, Senior Director Product Strategy, Manhattan Associates Inc. Engaging sales & marketing stakeholders in your S&OP processes to create demand visibility, while considering manufacturing constraints to design ideal inventory targets Identifying key vulnerability points of the supply chain to identify where safety stock may be needed, how to manage that safety stock and where lean is not an option Finding the sweet spot between being cost effective and being flexible to adapt inventory levels should inventory suddenly increase or decrease Collaborating with suppliers and using alternative suppliers Ensuring and developing an end to end visibility Value stream mapping – where are we now and where are the areas that we can improve Setting the right processes to assist product managers Focusing in on variation, not just averages Wayne Swanton VP Supply Chain, Watson Pharmaceuticals Mark Holder Senior Director, Global Supply Planning, AstraZeneca Pharmaceuticals JB Wilcox Senior Director- Supply Chain, Mylan Michael Trocchia Director Project Management- Supply Chain Management, Novartis Pharmaceuticals Corporation Roddy Martin Supply Chain Transformation Thought Leader, Kinaxis Roddy Martin has been working with Kinaxis since June 2012. He has worked with CCI since 2010 and before that was employed at AMR Research for 12 years as SVP, Research Fellow and Distinguished Analyst. Roddy was instrumental in building the demand –driven supply chain research and strategy team at AMR Research that operated as trusted advisors to leading global companies. Roddy has a millwright t [read more] Rodney Daugherty Senior Director Product Strategy, Manhattan Associates Inc. Rod Daugherty is the Senior Director of Product Strategy for the Demand Forecasting and Inventory Optimization solutions at Manhattan Associates where he oversees the product direction for these applications. For the last 18 years Rod has been a consultant, designer and product director for multiple replenishment software companies. Prior to his career in Inventory Optimization software Rod held v [read more]

10.15 INTERACTIVE DISCUSSION: Sharing Results Of The LogiPharma Benchmarking Study To Gauge Where The Companies Are On The Industry’s Most Pressing Issues 3 months prior to LogiPharma, the LogiPharma Advisory Board conducted an industry benchmarking study with a set of questions focusing on how companies are responding to the industry’s most pressing issues. Topics ranged from regulatory and compliance, drug shortages, security, serialization, the latest metrics to review performance, the global supply chain and more. In this panel led by the LogiPharma Advisory Board an interactive discussion will be created to share these results and hear the latest from where the industry is on your most pressing issues.

10.40 Morning Networking Break Morning Networking Break

11.10 Green & Cold Chain Supply Chain Roundtables Jeff Simmons, Manager External Manufacturing, , Daiichi Sankyo Michelle Johnson, Supply Chain Advisor , Cubist Pharmaceuticals Roundtable #1: Value Chain- Creating The Connection Between The Clinical & Commercial Supply ChainRoundtable #2: Discovering The Latest Technology Developments To Overcome Limited Capacity And Cold Chain Resource ShortagesRoundtable #3: Implementing Green Logistics Practices To Enhance Environmental Responsibility Without Impacting The Bottom LineRoundtable #4: Managing Rising Costs By Validating And Qualifying Quality Management Systems To Comply With Cold Chain And Temperature Control Requirements Jeff Simmons Manager External Manufacturing, , Daiichi Sankyo Michelle Johnson Supply Chain Advisor , Cubist Pharmaceuticals

1.10 Networking Lunch Networking Lunch

2.10 Adapting To Change: Breaking Down Timelines & Implementation Strategies To Acquire New Product Lines & Merge Them Into Your Existing Supply Chain Michael Daly, Director Supply Chain & International Operations, Valeant Pharmaceuticals When you go through a merger, you put together a checklist and try and get your data set, try to understand the issues, timing, when FDA will approve, how the board of directors etc. There are a lot of issues that can be learned with regards to the timeline and checklist aspect. So how do you prepare for it? Implementing operational aspects of pre M & A in relation to data and review Discovering how to create more time to manage your added responsibilities when the acquisition takes an additional 15-20 extra hours per week Finding out how to react to the new supply chain How do you integrate planning, inventory management and s & op between the two companies? Determining the pit falls and mitigation measures that senior managers can apply under such time constraints to minimize risks Michael Daly Director Supply Chain & International Operations, Valeant Pharmaceuticals

2.40 The 2020 Supply Chain- Looking Into The Crystal Ball To Assess Which Products Are Coming Out And How To Prepare To Ensure You Launch The Right Product At The Right Time In The Right Facility As a concluding session to the event, we will investigate what the supply chain of the future may look like. This session will investigate: Evaluating what the key differences are between the supply chain now and what it will look like 15 years from now: How do we create an optimized solution? Assessing your product portfolio at a very high level by trying to anticipate products emerging in the next 10-15 years by looking at what is currently being developed in R & D What tools are in place to make the best decisions around those drugs? Using the assumption that 20% of drugs will make it to the market: How do you practically manage and prepare for this? When do you start building the supply chain capabilities for this? When do you start negotiating with contract manufacturers?

3.10 Close Of LogiPharma 2012 Close Of LogiPharma 2012